Prostate Cancer

Manish Kohli, MD, discusses drugs that have been evaluated in metastatic castration-resistant prostate cancer.

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses treatment selection in newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC).

R. Steven Paulson, MD, discusses molecular testing in oncology.

Elisabeth I. Heath, MD, FACP, discusses a remaining challenge in nonmetastatic castration-resistant prostate cancer.

Phillip J. Koo, MD, division chief of Diagnostic Imaging, Banner MD Anderson Cancer Center, discusses the use of metastasis-directed therapy in prostate cancer.

The FDA has granted a priority review designation to a supplemental new drug application for olaparib (Lynparza) for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or suspected deleterious or somatic homologous recombination repair gene mutations, and who have also progressed on prior therapy with a new hormonal agent.

James L. Mohler, MD, discusses the need for genetic counselors in the detection and treatment of prostate cancer.

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the use of next-generation radiopharmaceuticals in prostate cancer.

The FDA has granted a priority review designation to a supplemental new drug application for rucaparib for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer.

Hussein Aoun, MD, a radiologist at Barbara Ann Karmanos Cancer Institute, discusses the imaging modalities that are currently being used in prostate cancer and how they compare with conventional imaging modalities.

The Society for Immunotherapy of Cancer is developing a growing menu of guidelines with treatment algorithms for specific cancer types to help practicing oncologists navigate the appropriate use of this emerging modality.

Celestia S. Higano, MD, FACP, provides perspective on data from the CARD trial and their implications on clinical practice.

Sam S. Chang, MD, MBA, discusses the evolution of surgical techniques in prostate cancer.

Elisabeth I. Heath, MD, FACP, discusses apalutamide, enzalutamide, and darolutamide, which have all been approved for use in nonmetastatic castration-resistant prostate cancer.

Clara Hwang, MD, discusses factors that can be used to decide what agent to use in the frontline setting for patients with metastatic castration-sensitive or castration-resistant prostate cancer.

Hussein Aoun, MD, discusses the use of novel imaging modalities and contrasted them with conventional imaging tools in prostate cancer.

Clara Hwang, MD, discusses key trials that have shaped the current treatment paradigms of metastatic castration-sensitive prostate cancer and metastatic castration-resistant prostate cancer.

Elisabeth I. Heath, MD, FACP, discusses the safety profiles of apalutamide, enzalutamide, and darolutamide in nonmetastatic castration-resistant prostate cancer.

Matthew R. Smith, MD, PhD, discusses key facets of darolutamide (Nubeqa) therapy in the treatment of patients with nonmetastatic prostate cancer.

Elisabeth I. Heath, MD, FACP, discusses 3 pivotal trials and how they have impacted clinical practice in nonmetastatic castration-resistant prostate cancer.

The FDA has approved a supplemental new drug application for enzalutamide (Xtandi) for the treatment of patients with metastatic castration-sensitive prostate cancer.

Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type.

Kelvin Alexander Moses, MD, PhD, discusses recent trials in metastatic hormone-sensitive prostate cancer.

William K. Oh, MD, discusses remaining challenges in metastatic hormone-sensitive prostate cancer.